Log in
ASX:PXS

Pharmaxis Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.09
MA: A$0.09
A$0.09
52-Week Range N/A
Volume721,139 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-2-94547200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.62 million
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PXS News and Ratings via Email

Sign-up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pharmaxis (ASX:PXS) Frequently Asked Questions

How were Pharmaxis' earnings last quarter?

Pharmaxis Ltd. (ASX:PXS) announced its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter.
View Pharmaxis' earnings history
.

Who are some of Pharmaxis' key competitors?

What other stocks do shareholders of Pharmaxis own?

Who are Pharmaxis' key executives?

Pharmaxis' management team includes the following people:
  • Mr. Gary Jonathan Phillips, CEO & Director (Age 58)
  • Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 63)
  • Mr. Wolfgang G. Jarolimek B.Sc. Ph.D., Head of Drug Discovery (Age 55)
  • Dr. Brett Charlton MBBS Ph.D., Medical Director (Age 63)
  • Ms. Kristen Morgan BSc, PGDipBusAdmin, MMedSc, Officer of Alliance Management & Medical and Regulatory Affairs (Age 47)

What is Pharmaxis' stock symbol?

Pharmaxis trades on the ASX under the ticker symbol "PXS."

How big of a company is Pharmaxis?

Pharmaxis has a market capitalization of $0.00 and generates $12.62 million in revenue each year. Pharmaxis employs 64 workers across the globe.

What is Pharmaxis' official website?

The official website for Pharmaxis is www.pharmaxis.com.au.

How can I contact Pharmaxis?

Pharmaxis' mailing address is 20 Rodborough Rd, FRENCHS FOREST, NSW 2086, Australia. The company can be reached via phone at +61-2-94547200.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.